Investigational drug · Phase 3
bivalent enterovirus vaccine
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Hand, Foot, and Mouth Disease(HFMD), Hand, Foot and Mouth Disease, Herpangina.
Phase 3Last checked: Nov 20, 2026Latest source record: Jun 26, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
3
Any phase or sponsor naming "bivalent enterovirus vaccine"
First trial start
2023
Sep 20, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "bivalent enterovirus vaccine", any sponsor or status.
Conditions studied
As listed on its trial records.
- Hand, Foot, and Mouth Disease(HFMD)
- Hand, Foot and Mouth Disease
- Herpangina
Largest trials
Live from ClinicalTrials.gov: studies naming "bivalent enterovirus vaccine" as an intervention, largest first.
- Efficacy, Safety, and Immunogenicity of the Bivalent Inactivated Enterovirus Vaccine (Vero Cell)Pivotal-lookingRecruiting
Sinovac Biotech Co., LtdIndustry
NCT06734832 · 8,000 participants (planned) · Start Dec 13, 2024 · Primary completion Nov 30, 2025
Drug: bivalent enterovirus vaccine (Vero cell), inactivated; Enterovirus Type 71 Vaccine (Vero Cell), Inactivated · For: Hand, Foot, and Mouth Disease(HFMD)
Sites: Hefei, China; Fujian, China; Guangdong, China · 4 sites in all
- Inactivated Bivalent Enterovirus Vaccine (Vero Cell) Phase I/II Clinical TrialPivotal-lookingCompleted
Sinovac Biotech Co., LtdIndustry
NCT06063057 · 744 participants · Start Sep 20, 2023 · Primary completion Dec 19, 2025
Drug: low dose Bivalent Enterovirus Vaccine (Vero Cell), Inactivated; medium dose Bivalent Enterovirus Vaccine (Vero Cell), Inactivated and 2 more · For: Hand, Foot and Mouth Disease; Herpangina
Sites: Chuxiong, China
- Phase I Clinical Trial of Enterovirus Type71 - Coxsackievirus Type A16 Bivalent VaccinePivotal-lookingNot yet recruiting
Institute of Medical Biology, Chinese Academy of Medical SciencesAcademic, hospital or other
NCT07326878 · 144 participants (planned) · Start Dec 30, 2025 · Primary completion Aug 15, 2026
Drug: Low Dose Enterovirus Type71 - Coxsackievirus Type A16 bivalent vaccine, inactivated (human diploid cell); Medium Dose Enterovirus Type71 - Coxsackievirus Type A16 bivalent vaccine, inactivated (human diploid cell) and 2 more · For: Hand, Foot and Mouth Disease (HFMD); HFMD; Hand, Foot and Mouth Disease
Sites: Chongqing, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.